View Post

Killing ‘Sleeper Cells’ May Prevent Relapse in ER+ Breast Cancer Therapy

In Clinical Studies News by Barbara Jacoby

By: Alana Hippensteele, Editor From: pharmacytimes.com The anti-cancer medicine venetoclax may improve the current therapy for estrogen receptor-positive (ER+) breast cancer, according to preclinical studies.1 Led by Walter and Eliza Hall Institute researchers, the new study used breast cancer cells taken from patients and demonstrated that venetoclax was effectively able to kill sleeping, or ‘senescent,’ cancer cells.1 The results from …

View Post

AbbVie, Roche leukemia drug successful in Phase III confirmatory study

In Clinical Studies News by Barbara Jacoby

By: Alaric DeArment From: medcitynews.com The companies said Venclexta extended overall survival in untreated acute myeloid leukemia patients when combined with Bristol-Myers Squibb’s VidazaVenclexta. A prior Phase III confirmatory trial, combining the drug with low-dose cytarabine, failed. A cancer drug made by Chicago-based AbbVie and Swiss drugmaker Roche was successful in a Phase III confirmatory trial in an aggressive form …

View Post

Venetoclax Is A Powerful New Kind of Cancer Drug Effective In Chronic Lymphocytic Leukemia

In In The News by Barbara Jacoby

By: Elaine Schattner From: forbes.com If there’s one message I’d take home from the annual meeting of the American Society of Hematology (ASH) in Orlando, concerning blood cancers – like leukemia, lymphoma and multiple myeloma – it’s that there are a lot of new drugs for doctors and patients to know about, consider and possibly try. If I had to …